RUNX1 and acute myeloid leukemia: Thus, although other proteins might be affected by inhibition by 4× PLDLS, the fact that EVI1-expressing cells are more sensitive to the effect of PLDLS inhibition suggests that there is a therapeutic window for targeting this interaction in AML patients.